Healthcare
Live Price
Offline$127.00
+1.63% today
1Y Change
+7.57%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Teleflex Incorporated (TFX) is a Healthcare stock with a market cap of $5.39B and listed on NYSE. The stock last traded around $127.00 and up 7.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -34.6%, EPS growth of -1462.4%, a dividend yield of 1.1%. What stands out right now is revenue -34.6%, EPS -1462.4%, free cash flow -51.8% with operating margin 9.7% and ROIC 4.3%. The dividend is present but secondary, with a yield around 1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TFX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TFX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TFX Max Drawdown
-24.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TFX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.8B
+0.7% YoY
FY Net Income
$485.4M
+33.7% YoY
Free Cash Flow
$579.8M
+120.5% YoY
Revenue Growth
-34.6%
EPS Growth
-1462.4%
Gross Margin
53.3%
Net Margin
-30.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.0B | 3.0B | 3.0B | 2.8B | 2.8B |
| Gross Profit | 1.1B | 1.7B | 1.6B | 1.5B | 1.5B |
| Operating Income | 256M | 151M | 506M | 500M | 628M |
| EBITDA | 303M | 434M | 761M | 731M | 854M |
| Net Income | -906M | 70M | 356M | 363M | 485M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 393M | 290M | 223M | 292M | 445M |
| Total Assets | 6.9B | 7.1B | 7.5B | 6.9B | 6.9B |
| Total Liabilities | 3.8B | 2.8B | 3.1B | 2.9B | 3.1B |
| Shareholder Equity | 3.1B | 4.3B | 4.4B | 4.0B | 3.8B |
| Total Debt | 2.7B | 1.8B | 1.9B | 1.8B | 2.0B |
| Net Debt | 2.3B | 1.5B | 1.7B | 1.5B | 1.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
651M
+90.4% YoY
Capital Expenditures
72M
+9.6% YoY
Free Cash Flow
580M
+120.5% YoY
Key ratios
Gross Margin
53.3%
Operating Margin
9.7%
Net Margin
-30.6%
ROE
-23.7%
Debt / Equity
0.87x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.